Willow Biosciences Stock Performance
| WLLW Stock | CAD 0.03 0.01 14.29% |
The firm maintains a market beta of -2.15, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Willow Biosciences are expected to decrease by larger amounts. On the other hand, during market turmoil, Willow Biosciences is expected to outperform it. At this point, Willow Biosciences has a negative expected return of -0.0411%. Please make sure to check out Willow Biosciences' total risk alpha, maximum drawdown, skewness, as well as the relationship between the treynor ratio and potential upside , to decide if Willow Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Willow Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Willow Biosciences is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 11 M | |
| Free Cash Flow | -11.5 M |
Willow |
Willow Biosciences Relative Risk vs. Return Landscape
If you would invest 5.50 in Willow Biosciences on December 23, 2024 and sell it today you would lose (2.50) from holding Willow Biosciences or give up 45.45% of portfolio value over 90 days. Willow Biosciences is generating negative expected returns and assumes 13.0568% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Willow on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Willow Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Willow Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Willow Biosciences, and traders can use it to determine the average amount a Willow Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0031
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | WLLW |
Estimated Market Risk
| 13.06 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Willow Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Willow Biosciences by adding Willow Biosciences to a well-diversified portfolio.
Willow Biosciences Fundamentals Growth
Willow Stock prices reflect investors' perceptions of the future prospects and financial health of Willow Biosciences, and Willow Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Willow Stock performance.
| Return On Equity | -2.59 | |||
| Return On Asset | -0.82 | |||
| Profit Margin | (2.69) % | |||
| Operating Margin | (0.60) % | |||
| Current Valuation | 5.23 M | |||
| Shares Outstanding | 144.2 M | |||
| Price To Earning | 4.00 X | |||
| Price To Book | 22.19 X | |||
| Price To Sales | 1.51 X | |||
| Revenue | 1.17 M | |||
| EBITDA | (11.63 M) | |||
| Cash And Equivalents | 11.01 M | |||
| Cash Per Share | 0.19 X | |||
| Total Debt | 2.16 M | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (10.92 M) | |||
| Earnings Per Share | (0.05) X | |||
| Total Asset | 6.67 M | |||
| Retained Earnings | (121.69 M) | |||
About Willow Biosciences Performance
By examining Willow Biosciences' fundamental ratios, stakeholders can obtain critical insights into Willow Biosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Willow Biosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada. Willow Biosciences Inc. was incorporated in 1981 and is headquartered in Calgary, Canada. WILLOW BIOSCIENCES is traded on Toronto Stock Exchange in Canada.Things to note about Willow Biosciences performance evaluation
Checking the ongoing alerts about Willow Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Willow Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Willow Biosciences generated a negative expected return over the last 90 days | |
| Willow Biosciences has high historical volatility and very poor performance | |
| Willow Biosciences has some characteristics of a very speculative penny stock | |
| Willow Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 1.17 M. Net Loss for the year was (13.03 M) with loss before overhead, payroll, taxes, and interest of (2.07 M). | |
| Willow Biosciences has accumulated about 11.01 M in cash with (10.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 24.0% of the company outstanding shares are owned by insiders |
- Analyzing Willow Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Willow Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Willow Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Willow Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Willow Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Willow Biosciences' stock. These opinions can provide insight into Willow Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Willow Stock
Willow Biosciences financial ratios help investors to determine whether Willow Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Willow with respect to the benefits of owning Willow Biosciences security.